Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05591547 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen
A Phase 2 study of Breast Cancer, sponsored by Sanford Health.
- Active
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
- 2
- Study locations
NCT05591547: Active Phase 2 study of Breast Cancer, sponsored by Sanford Health.
NCT05591547 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by Sanford Health. The registered enrollment target is 91 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05591547, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by Sanford Health.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will use an adjuvant radiation therapy regimen called APBI (accelerated partial breast irradiation). APBI is a treatment option available to women considered to have an early stage, low-risk breast cancer. The standard external beam-based APBI treatment delivers treatments every other day for five treatments, over ten calendar days. The APBI in this study is modified and will deliver five once daily treatments over consecutive treatment days, with a slightly lower dose of radiation each day as compared to the standard external beam-based APBI treatment.
Conditions Studied
Interventions
- RADIATION IMRT/VMAT-Based Accelerated Partial Breast Irradiation
Study Locations (2)
Minnesota
- Sanford Health - Worthington
South Dakota
- Sanford Health - Sioux Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2022-03-30 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05591547
The ClinicalTrials.gov registry entry for NCT05591547 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Sanford Health, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which IMRT/VMAT-Based Accelerated Partial Breast Irradiation is the first listed.
NCT05591547 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, South Dakota.
Frequently Asked Questions
What is clinical trial NCT05591547 about?
NCT05591547 is a clinical study titled "Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen". This study will use an adjuvant radiation therapy regimen called APBI (accelerated partial breast irradiation). APBI is a treatment option available to women considered to have an early stage, low-risk breast cancer. The standard external beam-based APBI treatment delivers treatments every other day...
What is the current status of trial NCT05591547?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2022-03-30. Estimated completion is 2027-06.
What conditions does trial NCT05591547 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05591547?
The interventions under investigation include: IMRT/VMAT-Based Accelerated Partial Breast Irradiation (RADIATION).
Who is sponsoring clinical trial NCT05591547?
This trial is sponsored by Sanford Health, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05591547 being conducted?
This trial has 2 study locations across Minnesota, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.